Skip to main content
. 2022 Jan 4;85(1):31–45. doi: 10.3233/JAD-210525

Table 2.

Availability of systematically collected biomarker data at baseline and/or follow-up in CONCORD-AD network cohorts

Biomarker AIBL BioFINDER-1 MCSAa,d
CU MCI AD CUb MCI AD CU MCI AD
Measures of Aβ, n (%)
  PET 145 (12)c 36 (12)c 19 (6)c 272 (33) 169 (58) N/A 1,592 (39)c 156 (28)c N/A
  CSF Aβ42 27 (2) 33 (11) 140 (44) 797 (96) 288 (99) 93 (100) 719 (18)c 64 (11) N/A
Measures of Tau, n (%)
  PET N/A N/A N/A 52 42 2 579 (14)c 35 (6) N/A
  CSF pTau 27 (2) 33 (11) 140 (44) 797 (96) 288 (99) 93 (90) 719 (18)c 64 (11) N/A
  CSF tTau 27 (2) 33 (11) 140 (44) 797 (96) 288 (99) 93 (100) 719 (18)c 64 (11) N/A

Aβ, amyloid-β; AD, Alzheimer’s disease; AIBL, Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing; AMI, AGRICA-MSA-Institut fédératif de recherche en santé publique/Aging Multidisciplinary Investigation; BioFINDER-1, Biomarkers For Identifying Neurodegenerative Disorders Early and Reliably; CSF, cerebrospinal fluid; CU, cognitively unimpaired; MCI, mild cognitive impairment; MCSA, Mayo Clinic Study of Aging; N/A, not available; ND, non-demented; PET, positron emission tomography; pTau, phosphorylated tau; tTau, total tau; 3C Bordeaux, Three-City Study. aIn MCSA, PET and/or CSF biomarkers could be available at baseline and/or follow-up visits and not necessarily at the same study visit, as participants can select if they would like to undergo PET scans and/or lumbar puncture every time they visit the study. Follow-up visits occur every 15 months and neuroimaging studies are offered every 30 months or sooner if the participant’s cognitive status changes (e.g., progresses from CU to MCI). bBioFINDER-1 CU group also included individuals with SCD. cLongitudinal data available. dMCSA did not actively follow-up participants diagnosed with dementia at study baseline.